Business
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
CALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX &...
About this update from Xortx Therapeutics, Inc.
[{"type":"text","content":"XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus BiosystemsAcquisition includes novel new chemical entity VB4-P5 with potential to address significant unmet needs in rare and large-market kidney diseases\n\n\n\n CALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“\n \n XORTX\n \n ” or the “\n \n Company\n \n ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has entered into a binding term sheet (the “Term Sheet”) to acquire a Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited, an Australian Securities Exchange listed company (“Vectus”). The program includes a\n \n novel new chemical entity, VB4-P5\n \n , along with its associated intellectual property, regulatory documentation, and manufacturing data. The program is currently at the\n \n pre-IND (Investigational New Drug)\n \n stage of development and targets both rare and prevalent forms of kidney disease — areas with substantial unmet medical need.\n \n\n Dr. Allen Davidoff, Chief Executive Officer of XORTX, stated, “The opportunity to acquire the VB4-P5 program was highly compelling. This program is underpinned by a novel, patented small molecule with robust global patent protection and strong preclinical evidence. It is directly aligned with our strategic focus on developing innovative therapies for progressive kidney disease, and it builds upon our mission to bring new classes of treatments to patients suffering from rare renal disorders.”\n \n\n The Term Sheet provides for XORTX to acquire from Vectus the intellectual property specifically related to the VB4-P5 compound and the data generated by Vectus from its work on the VB4-P5 small molecule and related assets. The consideration receivable by Vectus is USD $3.0 million, payable in common shares or common share equivalents of XORTX (the “\n \n Securities\n \n ”) at a deemed issue price of USD $0.86 per Security (the “\n \n Issue Price\n \n ”), with the Issue Price subject to adjustment in certain circumstances provided, however, that the Issue Price will not below lower than the Discounted M...